About: Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceutical products for oncology in Australia and the United States. The company's lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.
Sector: Healthcare
Industry: Biotechnology
Latest price: A$1.67 (+6.71%)
CU6 ASX Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd share price
CU6 price activity
Last Price
$1.670
Change (24hr)
0.11 AUD (6.71%)
Volume
4.41M
Volume (4w avg)
-
Open
$1.58
Day Range
$1.58 - $1.69
Previous Close
$1.57
Last Trade
29 Oct, 6:17 am GMT+0
Delayed
29 Oct, 6:17 am GMT+0
CU6 price performance
Delayed
29 Oct, 6:17 am GMT+0
CU6 Market Signals